Sickle Cell Anemia Testing & Screening Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: STRECK, INC., BioMedomics Inc., Laboratory Corporation of America Holdings

The global Sickle Cell Anemia Testing & Screening market reached a value of US$ 960.81 million in 2021. Looking ahead, the market is expected to reach $ 1,775.23 million by 2027, growing at a CAGR of 13.90% between 2022 and 2027.

Sickle Cell Anemia Testing & Screening Market Overview

The sickle cell disease (SCD) is one of a set of genetic conditions known as hemoglobinopathies, which develop when the defective hemoglobin damages and deforms RBCs. Millions of people around the world suffer from sickle cell disease, which is more common in sub-Saharan Africa, the Western Hemisphere, India, Saudi Arabia, and the Mediterranean region. Early diagnosis of the affected population becomes essential because there is no readily accessible treatment for people with sickle cell anemia. SCD has received little attention from the global health community, especially in developing places where the illness frequency has increased. This is because patients, the general public, and healthcare policymakers functioning locally in these regions are not aware of the disease.

Newborn screening program have been piloted in a number of sickle cell anemia-affected countries, including Ghana, the Democratic Republic of the Congo (DRC), Kenya, and Benin. Successful disease management in the aforementioned nations has forced developing economies to impose neonatal program, thus fueling the market's expansion. The development of non-invasive, portable, and digital technology to make SCD detection easier is expected to help remove obstacles to focused sickle cell diagnosis and medication administration. POC devices now being developed are based on approaches including microfluidic electrophoresis, lateral flow immunoassay, and densitometry.

Industry News and Updates:

April 06, 2021: Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy--

Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test, which allows for more precise measurements of Hb F, also known as fetal hemoglobin. The increased accuracy could be useful for monitoring hydroxyurea therapy in point-of-care settings.

What are the major Applications, Types and Regions for Sickle Cell Anemia Testing & Screening Market?

Market is segmented based on the type, applications, companies and regions.

By Type, it is segmented into

• Hemoglobin Electrophoresis


• High-performance Liquid Chromatography (HPLC)


• Point-of-Care Tests


• Other

By Application, it is segmented into

• Newborn Screening (12 months and below)


• Adult Screening (25 to 60 years)


• Other Age Groups (1 to 25 & above 60 years)

Sickle Cell Anemia Testing & Screening Market Regional Analysis

North America topped the market in 2019 with a 27.0% share. Eight Canadian provinces and 50 U.S. states have implemented newborn screening programmes, which has facilitated the growth of the market's active players. In poor nations like Africa and Asia, there are well-established standards for creating and conducting neonatal screening programmes for sickle cell disease. Sickle cell screening programmes are generally advised in areas where the illness is prevalent at a prevalence of 0.05 percent or higher. The systematic or targeted screening of all neonates for haemoglobin C or the sickle cell trait is a component of these screening programmes.

Currently, very few nations have implemented newborn screening programmes at the national level, owing to a lack of sufficient facilities to carry out newborn screening programmes. Recently, the Asia Pacific region, particularly India, has seen an increase in awareness and acceptance of neonatal sickle cell screening. Furthermore, many poor nations are creating measures to solve issues associated with high-income countries' newborn screening programmes, including speeding follow-up screening or diagnosis. In the near future, this is expected to give the Asia Pacific market a major boost.

• North America
  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East & Africa
  
  
  • Latin America
  
  
  
  

The Sickle Cell Anemia Testing & Screening Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Sickle Cell Anemia Testing & Screening Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

What is our Sickle Cell Anemia Testing & Screening Market report scope?

Key Takeaways from this Sickle Cell Anemia Testing & Screening Market Report

• Evaluate Sickle Cell Anemia Testing & Screening market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, end use applications and by different industry verticals.


• Understand the different dynamics influencing the market - growth driving factors, specific challenges and hidden opportunities.


• Get in-depth insights on your competitor performance – revenue, shares, business strategies, financial benchmarking, product benchmarking, SWOT analysis and more.


• Analyze the sales and distribution channels across geographies to enhance top-line revenues.


• Understand the demanding supply chain with a deep dive on the value augmentation at each, in order to optimize value and bring efficiencies in your processes.


• Get a quick outlook on the Sickle Cell Anemia Testing & Screening market entropy - M&A's, deals, partnerships, product launches of all key players for the past 4 years.


• Evaluate the import-export statistics, supply-demand and competitive landscape for more than top 20 countries globally for the market.

Frequently Asked Questions

What is the growth rate of Sickle Cell Anemia Testing & Screening Market?

The Sickle Cell Anemia Testing & Screening Market is growing at a CAGR of 13.90% over the next 5 years.

Who are the key players in Sickle Cell Anemia Testing & Screening Market?

STRECK, INC., BioMedomics Inc., Laboratory Corporation of America Holdings, Silver Lake Research Corporation, HEMEX HEALTH, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Quest Diagnostics, Daktari Diagnostics, Request A Test, Ltd., HALCYON BIOMEDICAL INCORPORATED, HEMOTYPE, Bio-Rad Laboratories, Inc.

What are the significant types of Sickle Cell Anemia Testing & Screening Market?

Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), Point-of-Care Tests, Other

What are the major end-use applications of Sickle Cell Anemia Testing & Screening Market?

Newborn Screening (12 months and below), Adult Screening (25 to 60 years), Other Age Groups (1 to 25 & above 60 years)

All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.